

Curriculum Vitae

Personal information **Olli Tenhunen**

Work experience

1. Employer: Oulu University Hospital
 - Start date: 052021
 - End date:
 - Position: Senior Consultant, Chief Specialist
 - Activities: Specialist in Medical Oncology and Radiotherapy
 - Country: Finland
2. Employer: Oulu University Hospital
 - Start date: 112014
 - End date: 052021
 - Position: Consultant
 - Activities: Specialist in Medical Oncology and Radiotherapy
 - Country: Finland
3. Employer: Oulu University Hospital
 - Start date: 012014
 - End date: 122014
 - Position: Associate chief physician
 - Activities: Administration
 - Country: Finland
4. Employer: Finnish Medicines Agency FIMEA
 - Start date: 112009
 - End date:
 - Position: Senior Medical Officer
 - Activities: Clinical Assessor for Anticancer Medicinal Products
 - Country: Finland
5. Employer: National Agency for Medicines
 - Start date: 092007
 - End date: 112009
 - Position: Senior Medical Officer
 - Activities:
 - Country: Finland
6. Employer: Oulu University Hospital, Department of Oncology and Radiotherapy
 - Start date: 062008
 - End date: 072013
 - Position: Specialising physician
 - Activities: Specialist training in medical oncology
 - Country: Finland
7. Employer: University of Oulu, Department of Pharmacology and Toxicology
 - Start date: 012002
 - End date: 102006
 - Position: Researcher
 - Activities: Scientist, PhD student, cardiovascular and molecular pharmacology, mechanisms of signal transduction
 - Country: Finland
8. Employer: Haukipudas Municipal Health Care Center
 - Start date: 122005
 - End date: 082006
 - Position: Physician
 - Activities: General medicine
 - Country: Finland

Education and training

1. Subject: University of Helsinki
 - Start date: 112019
 - End date:
 - Qualification: Adjunct professor of pharmacology
 - Organisation:
 - Country: Finland
2. Subject: University of Oulu, Faculty of Medicine
 - Start date: 062008
 - End date: 082013
 - Qualification: Specialist in medical oncology and radiotherapy
 - Organisation:
 - Country: Finland
3. Subject: Finnish Medical Association
 - Start date: 012010
 - End date: 032012
 - Qualification: Special competence in pharmaceutical medicine
 - Organisation:
 - Country: Finland
4. Subject: University of Oulu

- Start date: 022004
 - End date: 102006
 - Qualification: Doctor of medical sciences, PhD
 - Organisation: Pharmacology
 - Country: Finland
5. Subject: University of Oulu, Faculty of Medicine
- Start date: 081998
 - End date: 022004
 - Qualification: M.D., licentiate of medicine
 - Organisation:
 - Country: Finland
6. Subject: Oulun Lyseon lukio
- Start date: 081995
 - End date: 051998
 - Qualification: High school graduation
 - Organisation:
 - Country: Finland

Additional information

Publications

1. Tenhunen O, Lasch F, Pean E, Schiel A, Turpeinen M. Single_Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: a Retrospective Cohort Study of Centralised European Marketing Authorizations between 2010_2019. *Clin Pharmacol Ther.* 2020 Jun 23. doi: 10.1002/cpt.1965. 2. Elmadani M, Khan S, Tenhunen O, Magga J, Aittokallio T, Wennerberg K, Kerkelä R. Novel Screening Method Identifies PI3K α , mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival. *J Am Heart Assoc.* 2019 Nov 5;8(21):e013018. doi: 10.1161/JAHA.119.013018. 3. Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP. Trastuzumab-induced cardiotoxicity and its risk factors in real_world setting of breast cancer patients. *J Cancer Res Clin Oncol.* 2018 Jun 5. doi: 10.1007/s00432_018_2682_9. 4. Laatikainen O, Miettinen J, Sneek S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients: a systematic review and meta-analysis. *Eur J Clin Pharmacol.* 2017 Dec;73(12):1539_1549. doi: 10.1007/s00228_017_2330_3. Epub 2017 Sep 5. 5. Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, Hill J, Hystad M, Jovinge S, Kyselović J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. *Eur J Heart Fail.* 2015 Oct 16. doi: 10.1002/ehf.422. 6. Piuhola J, Tenhunen O, Kerkelä R. Adverse cardiac effects associated with anticancer drugs. *Duodecim.* 2015;131(5):441_7. 7. Kelloniemi A, Szabo Z, Serpi R, Näpänkangas J, Ohukainen P, Tenhunen O, Kaikkonen L, Koivisto E, Bagyura Z, Kerkelä R, Leosdóttir M, Hedner T, Melander O, Ruskoaho H, Rysä J. The Early-Onset Myocardial Infarction Associated PHACTR1 Gene Regulates Skeletal and Cardiac Alpha-Actin Gene Expression. *PLoS One.* 2015 Jun 22;10(6):e0130502. 8. Moilanen AM, Rysä J, Kaikkonen L, Karvonen T, Mustonen E, Serpi R, Szabó Z, Tenhunen O, Bagyura Z, Näpänkangas J, Ohukainen P, Tavi P, Kerkelä R, Leosdóttir M, Wahlstrand B, Hedner T, Melander O, Ruskoaho H. *PLoS One.* 2015 Apr 27;10(4):e0124907. 9. Perjés Á, Skoumal R, Tenhunen O, Kónyi A, Simon M, Horváth IG, Kerkelä R, Ruskoaho H, Szokodi I. Apelin increases cardiac contractility via protein kinase C ϵ and extracellular signal-regulated kinase-dependent mechanisms. *PLoS One.* 2014 Apr 2;9(4):e93473. 10. Tenhunen O. How to assess assessments? *Ann Onc.* 2013, May;24(5):1138_40. Editorial. 11. Aro J, Tokola H, Ronkainen VP, Koivisto E, Tenhunen O, Ilves M, Szokodi I, Ruskoaho H, Rysä J. Regulation of cardiac melusin gene expression by hypertrophic stimuli in the rat. *Acta Physiol (Oxf).* 2013 Mar;207(3):470_84. 12. Moilanen AM, Rysä J, Serpi R, Mustonen E, Szabó Z, Aro J, Näpänkangas J, Tenhunen O, Sutinen M, Salo T, Ruskoaho H. (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function. *PLoS One.* 2012;7(7):e41404. 13. Serpi R, Tolonen AM, Huusko J, Rysä J, Tenhunen O, Ylä-Herttuala S, Ruskoaho H. Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. *Cardiovasc Res.* 2011 Jan 1;89(1):204_13. 14. Rysä J*, Tenhunen O*, Serpi R*, Soini Y, Nemer M, Leskinen H, Ruskoaho H. GATA-4 is an angiogenic survival factor of the infarcted heart. *Circ Heart Fail.* 2010 May 1;3(3):440_50. *equal contribution. 15. Luosujärvi H, Aro J, Tokola H, Leskinen H, Tenhunen O, Skoumal R, Szokodi I, Ruskoaho H, Rysä J. A novel p38 MAPK target dyxin is rapidly induced by mechanical load in the heart. *Blood Press.* 2010 Feb;19(1):54_63. 16. Serpi R, Tolonen AM, Tenhunen O, Pieviläinen O, Kubin AM, Vaskivuo T, Soini Y, Kerkelä R, Leskinen H, Ruskoaho H. Divergent effects of losartan and metoprolol on cardiac remodeling, C-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. *Clin Transl Sci.* 2009 Dec;2(6):422_30. 17. Tenhunen O, Rysä J, Ilves M, Ruskoaho H & Leskinen H. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 MAPK in the heart. *Circ Res.* 2006 Sep 1;99(5):485_93. 18. Tenhunen O, Soini Y, Rysä J, Ilves M, Tuukkanen J, Serpi R, Pennanen H, Ruskoaho H, Leskinen H. p38 kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. *FASEB J.* 2006 Sep;20(11): 1907_9. 19. Tenhunen O, Szokodi I, Ruskoaho H. Posttranscriptional activation of BNP gene expression in response to increased left ventricular wall stress: role of calcineurin and PKC. *Regul Pept.* 2005;Jun;128(3):187_196. 20. Tenhunen O, Sarman B, Kerkela R, Szokodi I, Papp L, Toth M, Ruskoaho H. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. *J Biol Chem.* 2004 Jun 4;279(23):24852_60. 21. Luodonpää M, Rysä J, Pikkariainen S, Tenhunen O, Tokola H, Puhakka J, Marttila M, Vuolteenaho O, Ruskoaho H. Mechanisms regulating adrenomedullin gene expression in the left ventricle: role of mechanical load. *Regul Pept.* 2003 Apr 15;112(1_3):153_9. 22. Hautala N, Tenhunen O, Szokodi I, Ruskoaho H. Direct left ventricular wall stretch activates GATA4 binding in perfused rat heart: involvement of autocrine/paracrine pathways. *Pflugers Arch.* 2002 Jan;443(3):362_9.

Projects

Memberships

Memberships in EMA Committees and Working Parties: Member, EMA CHMP Oncology Working Party, 2010_present Member, EMA CHMP Scientific Advice Working Party, 2014_present Alternate Member, EMA Committee for Advanced Therapeutics, 2012_2021 Memberships in scientific societies: Finnish Medical Association Finnish Society for Medical Oncology Finnish Pharmacological Society Finnish Society for Clinical Pharmacology Finnish Medical Society Duodecim

Other Relevant Information